Home

Rahul Nayar

CIK 1744923 · Chief Executive Officer · last filed 2020-12-28

Rahul Nayar is a Chief Executive Officer who has filed 3 SEC Form 4 insider transactions across 2 companies since 2018. The most recent filing, for RVPHW, was dated Dec 28, 2020. Across all open-market trades the lifetime net is +$3.4M, making them a net buyer over the disclosed history. 2 SEC filings were submitted jointly with PARAG SAXENA.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

2

Total Filings

3

Lifetime Open-Market Net

$3.43M

Filer Profile

Reported Address
250 WEST 55TH STREET
NEW YORK, NY 10019
Related Filers
PARAG SAXENA — 2 joint filings, latest 2020-12-28
Tenzing LLC — 2 joint filings, latest 2020-12-28
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPHW) Delisted 10%+ Owner 2,121,750 $0.00 $6.4K $0 1 2020-12-28
REVIVA PHARMACEUTICALS HOLDINGS, INC. (TZACU) Delisted Chief Executive Officer 1,924,250 — — $3.43M 2 2018-09-04

Recent Filings

3 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2020-12-28 REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPHW) Delisted Mixed +592,500 $0 EDGAR
2018-09-04 REVIVA PHARMACEUTICALS HOLDINGS, INC. (TZACU) Delisted Buy (P) +33,000 $330.0K EDGAR
2018-08-24 REVIVA PHARMACEUTICALS HOLDINGS, INC. (TZACU) Delisted Buy (P) +310,000 $3.10M EDGAR
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.